A pilot safety study and single arm phase II study of gemcitabine and cisplatin with atezolizumab (MPDL3280A) in patients with metastatic and muscle invasive bladder cancer respectively

Brief description of study

If you have been diagnosed with muscle-invasive bladder cancer, you may qualify for this study. The main goal of this study is to find out what effects, the study drug, atezolizumab has on your cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin.


Clinical Study Identifier: s16-02066
ClinicalTrials.gov Identifier: NCT02989584
Principal Investigator: Arjun Vasant Balar
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.